NuvOx Therapeutics, Inc. (NUOX)
NuvOx Therapeutics will go public soon, but the exact IPO date is still unknown.
IPO Price Range
$6.00 - $8.00
Shares Offered
2,860,000
Deal Size
$20.02M
Company Description
NuvOx Therapeutics is a clinical-stage biopharmaceutical company developing innovative oxygen therapeutic solutions for the treatment of diseases where hypoxia, or lack of oxygen, plays a critical role.
Our product candidate is NanO2, the API of which is dodecafluoropentane. NanO2 is administered intravenously as an emulsified liquid, containing nano-sized droplets that after entering the body, due to the human body temperature, convert to a gas, which enables them to deliver more oxygen than when in the liquid state.
The focus of our clinical research and development to date has been on the administration of NanO2 to treat acute ischemic stroke, GBM, ARDS, and sickle cell anemia.
NuvOx Therapeutics, Inc.
| Country | United States |
| Founded | 2008 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 9 |
| CEO | Rong Wang |
Contact Details
Address: 1635 E. 18th Street Tucson, AZ 85719 United States | |
| Phone | (520) 624-6688 |
| Website | nuvoxtherapeutics.com |
Stock Details
| Ticker Symbol | NUOX |
| Exchange | NYSEAMERICAN |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 1966126 |
Key Executives
| Name | Position |
|---|---|
| Evan Unger, M.D. | Executive Chairman of the Board |
| Rong Wang | President, Chief Executive Officer and Director |
| Shien McCullough, CPA | Interim Chief Financial Officer |
| Jennifer L. H. Johnson, Ph.D. | Chief Operating Officer |
| Richard Carmona, M.D. | Director |
| Jon S. Saxe | Director |
| Jonathan T. Schilling | Director |
| Marvin J. Slepian, M.D | Director |
| Wilson W. Cheung, CPA | Director |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Jul 17, 2026 | S-1 | General form for registration of securities under the Securities Act of 1933 |
| May 6, 2025 | DRS/A | [Amend] [Cover] Draft Registration Statement |
| Apr 8, 2025 | DRS/A | [Amend] [Cover] Draft Registration Statement |
| Dec 23, 2024 | DRS | [Cover] Draft Registration Statement |
| Nov 22, 2024 | D | Notice of Exempt Offering of Securities |
| Feb 15, 2023 | D | Notice of Exempt Offering of Securities |